# Melanotan II Peptide

> Melanotan II is a cyclic melanocortin agonist that stimulates pigmentation, tanning response, libido signaling, appetite effects, and nausea pathways.

Canonical: https://pepflow.app/peptides/melanotan-ii/

The Risky Tanner

Melanotan II is a synthetic cyclic melanocortin agonist developed from alpha-MSH analog chemistry. It is best known for tanning, libido, nausea, appetite, and pigmentation effects.

Skin appearance  Sexual function  Appetite and weight

Tier D

Evidence Preliminary

Safety High Caution

FDA status Not Approved

Last reviewed October 25, 2026 27 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Melanotan II?

Melanotan II is a synthetic cyclic melanocortin agonist developed from alpha-MSH analog chemistry. It is best known for tanning, libido, nausea, appetite, and pigmentation effects.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

Unlike bremelanotide or afamelanotide, Melanotan II is not an FDA-approved drug product. Regulators have warned against injectable tanning products and unapproved supply.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

Its broad melanocortin activity is the core issue: the same pathway that can darken skin or affect sexual response can also affect nausea, blood pressure, appetite, moles, and pigmentation safety.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

## What Melanotan II is investigated for

Melanotan II evidence is grouped by practical use case and injectable, oral, topical, and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Skin tanning and pigmentation Injectable 52% Emerging

Tanning is human-studied but not an approved or low-risk consumer use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

#### Human evidence

A pilot phase 1 study evaluated melanotan II pigmentation, while regulators warn against injectable tanning products.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

#### Animal / mechanistic evidence

Melanocortin receptor activity explains pigmentation effects, but safety and product-quality concerns are substantial.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

### ### Sexual function enhancement Injectable 45% Preliminary

Sexual-function discussion should point readers toward the stronger PT-141 evidence boundary.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

#### Human evidence

Early human melanotan II literature reported sexual-function effects, but PT-141/bremelanotide is the derivative with approved HSDD evidence.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

#### Animal / mechanistic evidence

Central melanocortin arousal biology supports the sexual-function signal.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

### ### Appetite and food-intake signaling Injectable 24% Limited

Appetite suppression is preclinical melanocortin signaling, not weight-loss evidence.[\[25\]](<https://pubmed.ncbi.nlm.nih.gov/22761160/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

#### Human evidence

Human appetite or weight-loss outcomes for melanotan II are not established in the cited literature.[\[25\]](<https://pubmed.ncbi.nlm.nih.gov/22761160/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

#### Animal / mechanistic evidence

Mouse work links melanotan II with food-intake reductions and energetic responses through melanocortin biology.[\[25\]](<https://pubmed.ncbi.nlm.nih.gov/22761160/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

## Evidence snapshot

### Overall confidence

Preliminary

45%

Melanotan II has visible melanocortin activity, but the evidence profile is constrained by unapproved injectable safety concerns. Pigmentation and sexual-function signals remain high-caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

52%

### Human evidence

Emerging

Human tanning effects have been observed, but unapproved injectable tanning use has major safety and regulatory concerns.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

34%

### Animal / preclinical

Limited

Melanocortin MC1R biology supports pigmentation effects.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

49%

### Mechanism support

Preliminary

Melanotan II activates multiple melanocortin receptors. MC1R activity supports eumelanin production, while central melanocortin effects help explain libido, appetite, nausea, and flushing.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

## Forms & administration

Melanotan II appears in unapproved injectable tanning products. Oral, topical and nasal formulations remain experimental, with evidence largely limited to animals. These forms differ in absorption and exposure; they do not provide established human alternatives to injection or the approved afamelanotide implant.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/7983590/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/31968661/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/28009464/>)

Injectable Oral Topical Nasal spray

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 250-500 mcg per dose.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>)

### Frequency

Usually taken once daily during the active phase.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>)

### Timing Considerations

Evening is the usual timing.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>)

### Cycle Length

Common cycles run 4-8 weeks.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>)

[Full Melanotan II dosage guide](<https://pepflow.app/peptides/melanotan-ii/dosage/>)

## What to expect

### First 1-2 weeks

Injectable Melanotan II tanning-oriented use may bring early pigment darkening, appetite change, libido change, or tanning-response shifts.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>)

### Weeks 2-6

Injectable tanning blocks may show progressive skin darkening, uneven pigmentation, appetite effects, and libido-pattern changes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>)

### After stopping

Pigmentation gradually fades after injectable Melanotan II use ends as skin turnover and sun-exposure patterns change.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>)

## Safety profile

Melanotan II safety is high-concern because unapproved injectable tanning use combines melanocortin effects, mole/pigmentation changes, cardiovascular symptoms, and product-quality risk.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

### Common side effects

- Nausea [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- Flushing [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- Appetite change [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- Libido change [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

### Cautions

- Moles / melanoma[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- Cardiovascular symptoms[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- Unapproved injectable[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

### What we don't know

Long-term melanoma risk, product purity, dose-response, and repeated-cycle cardiovascular safety remain unclear for Melanotan II.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

## Who Melanotan II is not for

Route-specific avoid and medical-review notes:

- **History of melanoma or concerning moles**

  History of melanoma or concerning moles warrants medical review or avoidance for Melanotan II.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for Melanotan II.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- **Uncontrolled cardiovascular disease**

  Uncontrolled cardiovascular disease warrants medical review or avoidance for Melanotan II.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Vasoactive sexual-function drugs**

  PDE5 inhibitors, nitrates, stimulants, or antihypertensives can compound flushing, dizziness, blood-pressure symptoms, or erection effects; this is a theoretical pathway caution.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- **Appetite / weight-loss drugs**

  GLP-1 drugs, stimulants, or appetite-suppressant supplements can add nausea and appetite suppression; this is a theoretical pathway caution.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- **Photosensitizers / tanning products**

  Photosensitizing drugs or tanning products can increase burn or skin-injury risk if Melanotan II encourages more UV exposure; this is a route-specific caution.[\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)

## Pairing notes

### Not recommended with

**Melanotan I: overlapping pigmentation effects** Injectable

Melanotan I and Melanotan II both activate melanocortin pathways that increase pigmentation. Using both duplicates melanocortin exposure, while Melanotan II also adds nausea, sexual-response, and poorly characterized systemic effects.[\[26\]](<https://pubmed.ncbi.nlm.nih.gov/9113347/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

**PT-141: added melanocortin effects** Injectable

PT-141 and Melanotan II both stimulate melanocortin receptors and can overlap nausea and sexual-response effects. Melanotan II additionally increases pigmentation and carries poorly characterized systemic risk.[\[27\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, Melanotan II is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · Melanotan II is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Flagged · FDA safety-risk materials flag Melanotan II for immunogenicity and impurity concerns, plus serious published case-report events. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Not Approved

Melanotan II is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Flagged

FDA safety-risk materials flag Melanotan II for immunogenicity and impurity concerns, plus serious published case-report events. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[17\]](<https://www.ema.europa.eu/en/medicines>) [\[18\]](<https://products.mhra.gov.uk/>) [\[19\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[20\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Melanotan II injectable route as athlete-cleared without sport-specific review.[\[9\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

Melanotan II activates multiple melanocortin receptors. MC1R activity supports eumelanin production in melanocytes, while central melanocortin effects can influence libido, appetite, nausea, flushing, and autonomic symptoms.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

Injectable systemic exposure is the practical concern because this is not just a local cosmetic pigment signal. Broad receptor activity, mole or pigmentation changes, cardiovascular symptoms, priapism reports, and product-quality uncertainty make the mechanism a caution point. This is why route-specific safety and dermatologic monitoring matter more than the tanning shorthand for human use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

## Research gaps & open questions

What the current literature has not yet settled about Melanotan II:

01

Long-term studies need to track persistent pigmentation, changes in moles, and other skin outcomes after repeated Melanotan II use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

02

Independent surveillance needs to show what unapproved Melanotan II products actually contain and how often contamination, mislabeling, or dosing errors occur.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

03

Direct comparisons are needed to understand how Melanotan II's safety differs from approved melanocortin medicines such as afamelanotide or bremelanotide.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

## Common questions

### Is Melanotan II FDA-approved?

No. Melanotan II is not FDA-approved in the U.S., and FDA lists it with significant compounding safety concerns.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

### Is Melanotan II a safe tanning shortcut?

No. Regulators warn against unapproved injectable tanning products, and pigmentation, mole changes, cardiovascular symptoms, and product quality are major issues.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>)

### Is Melanotan II the same as PT-141?

No. Bremelanotide/PT-141 has a specific FDA-approved indication, route, and label; Melanotan II does not.[\[7\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>)

## Myths & misconceptions

### Myth

A darker tan means safer sun exposure.

### Reality

Pigmentation does not replace sunscreen, UV avoidance, or mole monitoring.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

### Myth

Injectable tanning is just cosmetic.

### Reality

Injectable melanocortin agonists can affect nausea, blood pressure, appetite, libido, and moles.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)

## History & discovery

Melanotan II emerged from melanocortin analog research that tested tanning, sexual-response, and appetite-related biology. Its later history shifted toward unapproved injectable tanning-market risk. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

Pilot human studies observed pigmentation and sexual-response signals, along with tolerability issues. Those findings explain public fascination but did not produce an approved tanning medicine.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

Case reports and regulator warnings moved Melanotan II into a safety story about unapproved injections, pigmentation changes, cardiovascular symptoms, priapism, and product quality.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/8637402/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/11035391/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/31953620/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/16412534/>) [\[6\]](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)

## Published research 27 citations

- [\[1\] **Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.** Life Sci, 1996. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8637402/>)
- [\[2\] **Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.** Int J Impot Res, 2000 Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/11035391/>)
- [\[3\] **Melanotan II: a possible cause of renal infarction: review of the literature and case report.** CEN Case Rep, 2020 May. review.](<https://pubmed.ncbi.nlm.nih.gov/31953620/>)
- [\[4\] **Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.** Peptides, 2006 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/16412534/>)
- [\[5\] **Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.** Clin Toxicol (Phila), 2012 Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/23121206/>)
- [\[6\] **Melanotan and other injectable tanning products** Therapeutic Goods Administration. regulatory.](<https://www.tga.gov.au/news/safety-alerts/melanotan-and-other-injectable-tanning-products>)
- [\[7\] **Drugs@FDA/openFDA query for Melanotan II** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Melanotan%20II%22&limit=1>)
- [\[8\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[9\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[10\] **Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide.** Journal of pharmaceutical sciences, 1994 Aug. animal.](<https://pubmed.ncbi.nlm.nih.gov/7983590/>)
- [\[11\] **Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition.** International journal of molecular sciences, 2020 Jan 20. animal.](<https://pubmed.ncbi.nlm.nih.gov/31968661/>)
- [\[12\] **Effect of Melanotan-II on Brain Fos Immunoreactivity and Oxytocin Neuronal Activity and Secretion in Rats.** Journal of neuroendocrinology, 2017 Feb. animal.](<https://pubmed.ncbi.nlm.nih.gov/28009464/>)
- [\[13\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[14\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[15\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[16\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[17\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[18\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[19\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[20\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[21\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[22\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[23\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[24\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)
- [\[25\] **Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency.** Am J Physiol Endocrinol Metab, 2012 Sep 1. animal.](<https://pubmed.ncbi.nlm.nih.gov/22761160/>)
- [\[26\] **Skin pigmentation and pharmacokinetics of melanotan-I in humans.** Biopharm Drug Dispos, 1997 Apr. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/9113347/>)
- [\[27\] **Vyleesi bremelanotide prescribing information** U.S. Food and Drug Administration. official guidance.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Melanocortin pathway peptide

**Tier**

D

**Evidence**

45% Preliminary

**Safety**

High Caution

**FDA status**

Not Approved

**Injectable 503A**

Flagged

**Citations**

[27 citations](<https://pepflow.app/peptides/melanotan-ii/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Skin tanning and pigmentation
- Sexual function enhancement
- Appetite and food-intake signaling

### Common side effects

- Nausea
- Flushing
- Appetite change

### Also known as

- MT-II
- Melanotan 2
- MT-2
- Melanocortin analog

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Melanotan II dosage guide](<https://pepflow.app/peptides/melanotan-ii/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
